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Summary: Angiotensin-converting enzyme (EC 3.4.15.1) exhibhs distinctive tissue differences in
electrophoretic behaviour. Human tissue homogenates and biological fluids were subjected to agar gel and
polyacrylamide gel electrophoresis. The gels were cut into slices and enzymatic activity detected by a specific
colorimetric reaction. The technique allows localization of the enzyme in the electrophoretogram and gives
an estimate of the total enzymatic activity of a tissue or biological fluid. Several tissues were found to show
multiple forms of angiotensin-converting enzyme. The specificity of the assay was determined by running
the samples after the addition of captopril and by adding proteinase inhibitors to the incubation mixture.
Multiple Formen von Angiotensin-Converting Enzyme in Geweben und biologischen Flüssigkeiten des Menschen
Zusammenfassung: Angiotensin-Converting Enzyme (EC 3.4.15.1) weist von Gewebe zu Gewebe deutliche
Unterschiede im elektrophoretischen Verhalten auf. Gewebshomogenate und biologische Flüssigkeiten vom
Menschen wurden der Agargel- und Polyacrylamidgel-Elektrophorese unterworfen. Die Gele wurden in
Scheiben geschnitten und die katalytischen Aktivitäten mit einer spezifischen kolorimetrischen Reaktion
nachgewiesen. Das Verfahren erlaubt die Lokalisierung des Enzyms im Elektropherogramm und gestattet
eine Schätzung der katalytischen Gesamtaktivität in einem Gewebe oder einer biologischen Flüssigkeit. In
mehreren Geweben konnten multiple Formen von Angiotensin-Converting Enzyme nachgewiesen werden.
Die Spezifität des Verfahrens wurde durch vorherige Zugabe von Captopril bzw. Zugabe von Proteaseinhibito-
ren zum Inkubationsgemisch geprüft.
Ihtroduction
 roid therapy in this disease (1) Here we describe the
Angiotensin-converting enzyme (dipeptidyl carb- electrophoretic behaviour of angiotensin-converting
oxypeptidase, kininase H, EC 3.4.15.1)lis a membrane enzyme fröm human tissue homogenates and bio-
bound glycpprptein which mediates the cleavage of logical fluids. Detection of enzyme activity was
the dipeptide histidyl-leucine from the decapeptide carried out by a specific two-step colorimetric re-
angiotensin l to generate the octapeptide angio- action sequence developed by one of us (2).
tensinll; it .also catalyses bradykinin. degradation.
The assay of angiotensin-converting enzyme activity Angiotensin-converting enzyme was successfully puri-
in human serum is a useful tool for detecting clinically fied by a combination of Chromatographie and
active pulmonäry sarcoidosis and for monitoring ste- electrophoretical techniques. Heterogeneity of the
J. Clin. Chem. Clin. Biochem. / Vol. 23,1985 / No. 7
382 van Sande, Schärpe, Neels and Kasahara: Multiple forms of angiotensin-converting cnzyme
purified enzyme has been reported in several cases.
Fitz & Ovenwf(3) provided evidence for the existence
of more than one angiotensin-converting enzyme.
The elution pattern (Sephadex G-200) of an am-
monium sulphate precipitated preparation of human
lung showed two peaks of angiotensin-converting en-
zyme. The authors suggested that more than one
enzyme could be involved in the conversion of
angiotensin I, perhaps by causing sequential peptide
loss from the COOH-terminal of the molecule.
A 500-fold purification of converting enzyme from
human seminal plasma on Sephadex G-200 also
yielded 2 fractions with different moJecular weights.
Both were inhibited by the nonapeptide SQ 20,881
(4).
Oshima et al. (5) purified angiotensin-converting en-
zyme from hog kidney by a combination of several
Chromatographie techniques (DEAE-cellulose, cal-
cium php^phate gel, DEAE-Sephadex A-50,
hydroxylapatite, Sephadex G-200) and found in the
purified enzyme two protein bands on Standard disc
electrophoresis. A single protein component was
obtained in the gel after treatment with
neuraminidase (EC 3.2.1.18). The two bands were
both active enzymes, differing only in sialic acid con-
tent.
In homogenates of human placenta, Litrowicz &
Maloßejew (6) found, after enzyme Filtration on
Sephadex G-200, 3 protein peaks of converting
enzyme. After purification of converting enzyme from
human lung, Grönhagen-Riska & Fyhrquist (7)
showed one major and one faint band. These authors
suggested that the different enzymatic peaks in
Sephadex elutions represent polymeric forms of the
enzyme.
Using polyacrylamide gel electrophoresis, Hara et
al. (8) found two peaks of converting enzyme in
granulomatous lesions of the skin of patients with
beryllium-induced hypersensitivity. Two peaks with
the same mobility äs those from pathological sources
were also found in normal dermis. The aim of the
present study was to show the heterogeneity of con-
verting enzyme in crude tissue homogenates, using
the capacity to cleave histidyl-leucine from an artificäl
Substrate, äs well äs Inhibition with captopril in low
concentrations, äs criteria for the definition of the
enzyme.
The multiple forms of angiotensin-converting enzyme
lend support to the hypothesis of the existence of
enzymes with quantitatively different sialic acid con-«
tent in the homogenates and biological fluids studied.
Materials and Methods
Human mate r i a l
Serum was obtained from blood-bank donors, sperm from
healthy donors and prostatic fluid from vasectomized indivi-
duals. All fluids were frozen in liquid nitrogen and stored at
— 87 °C äs rapidly äs possible. The following tissues were
obtained from surgical patients: prostate (from patients with
prostate-carcinoma, or benign prostatic hypertrophy, or normal
prostate tissue from patients with bladder cancer), kidney,
testis, seminal vesicle, ductus deferens, bladder, stomach
(antrum), ileum, appendix, colon transversum, gall bladder,
rectum, spieen, vena saphena magna, skin, thyroid, signioid,
liver, lung, skeletal inuscle, ovary and bone marrow. These were
frozen äs soon äs possible in liquid nitrogen and stored at
-87°C.
Reagents
Hippuricase (EC 3.5.1.14) and the enzyme Substrate, /?-
hydroxybenzoyl-glycyl-L^histidyl-L-leucine were obtained from
Fujirebio Inc., Tokyo, Japan. The agar employed (Agar Noble)
was obtained from Difco, Detroit, Michigan, USA. Poly-
acrylamide reagents for disc electrophoresis were from
Eastman-Kodak, Rochester, N.Y., USA. Captopril (SQ 14225)
was a generous gift from Squibb, Belgium. Nonidet P40 was
from L.K.B., Bromma, Sweden. Soybean trypsin Inhibitor from
Worthington Biochemical Corporation, Freehold, N.J., USA.
N-ethyl-maleimide from Aldrich, Milwauky, Wisconsin,
pepstatin from Protein Research Foundation, Osako, Japan
and aprotinin from Bayer, F.R.G. Octyl-ß-/}-glycppyranoside
was from Calbiochem-Behring, La Jollä, California, USA.
Human albumin was obtained from Sigma Chemicals, St.
Louis, Missouri, USA, and Macrodex, a depolymerized dextran
(MT 40000) was from Povite, Christiaens, Brüssels, Belgium. All
othef reagents were of analytical grade (E. Merck, Darmstadt,
F.R.G.).
Tissue hoinogenization
Tissue homogenates were prepared by grinding the tissue in an
Ehejhem glass homogenizer with a teflon pestle, either by
adding one drop of Nonidet P40 per 200 mg tissue, or according
to the method of Lazo & Quinn
 :(9), which utilizes a 30 mmol/i
solution of octyl-ß-Z)-glycopyranoside.
Agar gel electrophoresis
After centrifugation at 50000 g for 30 min at 4 °C, the supernate
of the homogenized tissue was used for electrophoresis. Agar
gel electrophoresis was carried out äs described by Wieme
(10). Protein and enzyme electrophoresis was performed on
microscope slides (2.5 7.6 cm) covered with l mm 10 g/l agar
gel in a 0.04 mol/1 sodium barbital 0.09 mol/1 HC1 buffer (pH
8.4). Migration time was 25. min at 140 V. Along with the
sample, 3 of a mixture of human albumin (10 mg) and
Macrodex (0.2 ml) in l ml sodium barbital-HCl buffer was
applied below the sample application site.
After electrophoresis the region between the migration points
of albumin and Macrodex was cut into 10 slices. This distance
was taken arbitrarily äs one unit (1.00), and the relative mobility
(mr) of the detected enzymes assigned accordingly.
Polyacrylamide gel electrophoresis
Disc electrophoresis of tissue homogenates was carried out by
the procedure of Maurer (11).
Glass tubes (0.6 85 mm) were utilized and the gel consisted
of 75 g/l acrylamide, 2 g/l bis-acrylamide in a 0.08 mol/l
tris(hydoxymethyl)-aminomethane 0.16 mol/1 HC1 buffer (pH
7.5). The electrode buffer solution, (pH 7.0) consisted of 0.3
mol/1 diethylbarbituric acid^O.Ol 1^ 91/1 Tris. Bromophenol blue
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was used s a tracker dye. Electrophoresis was performed at
constant current (2.5 mA) per tube. After electrophoresis the
gel was cut into 15 equal parts, between the migration point
of albumin and the top of the gel.
Enzyme detection
Each slice of gel was incubated 16 h at 37 °C in a tube con-
taining 0.5 ml incubation mixture, consisting of 10 mmol/1
Substrate, (p-hydroxybenzoyl-Gly-L-His-L-Leu), 3 kU/1 hip-
puricase and 2.5 mmol/1 4-amino-antipyrine in a 0.12 mol/1
borate buffer (pH 8.3) containing 0.7 mol/1 sodium Chloride.
After the incubation, 1.5 ml of a Stopper and developer solution
containing NaIO4 6.5 mmol/1, 3 mmol/1 ethylene-
diaminetetraacetic acid and 2 g/l Triton X-100 was added to
each tube. The colour intensity produced by the quinoneimine
dye was measured at 505 nm with a Beckman model 25 spec-
trophotometer.
Detection of catalytic activity was carried out s follows:
/?-hydroxyhippuryl- conveftTngwzyme p-hydroxyhippuric
L-His-L-Leu
/,-hydroxyhippuric acid
/7-hydroxybenzoic acid Naio4
+ 4-amino-antipyrine
acid + L-His-L-Leu
p-hydroxybenzoic acid
+ glycine
quinoneimine dye
The specificity of the reaction sequence for angiotensin-con-
verting enzyme was tested by adding 0.1 ml l μιηοΐ/ΐ captopril
to each incubation tube. Controls run with no enzyme and
Substrate did not give any colour. For each biological fluid or
tissue, at least two specimens from different patients were
examin ed.
Results
Since the same sample volume (7 μΐ) wa$ employed
for each determination, the electrophoretic procedure
provides a relative estimation of the conVerting en-
zyme catalytic activity in the various tissues and fluids
examined. The enzyme appears widespread, but the
aniount of catalytic activity differs widely, depending
on the type of tissue examined.
The results obtained by gar gel electrophoresis are
represented in figure l, (a to j). For the sake pf clarity,
the results are shown in groups of low and high
enzyme activity.
Tissue homogenates with very high enzymatic activity
are diluted before electrophoresis with physiological
saline.
Benign prostatic hyperplasia has the highest
angiotensin-converting enzyme activity of all the
samples studied. Its major converting enzyme activity
migrates in agar gel with a mr = 0.75. This is also
the mr of the enzyme from prostatic fluid and of one
of the two peaks of seminal plasma. The latter also
has a very active component with mr = 0.45, coincid-
ing with the mr of the converting enzyme of seminal
vesicles. Further differences are exhibited by the en-
zyme from other tissues of the urogenital tract: con-
verting enzyme from kidney and bladder migrates at
mr = 0.55.
The enzyme from the tissues of the digestive tract,
e. g. sigmoid and stomach, also migrates differently
from those described above. The lower angiotensin-
converting enzyme activity in normal prostate and
prostate cancer than in benign prostatic hyperplasia
is remarkable, but the enzyme activities have the
same mr. In some tissues, an additional converting
enzyme activity was found, which moved slowly
(mr = 0.15) and showed a relatively small amount
of enzymatic activity.
Compared with agar gel, polyacrylamide gel elec-
trophoresis has a high resolving power for proteins,
particularily when a stacking gel is used. However,
the use of a stacking gel did not improve the enzyme
Separation. THe polyacrylamide gel results obtained
from some tissues are represented graphically in
figure 2. The patterns obtained are quite similar to
those obtained by agar gel electrophoresis. However,
one major difference is the enzymatic activity which
remains either in the stacking gel, or in the sucrose
solution in which the sample is added to the separat-
ing gel. The nature of this phenomenon is not clear,
but presumably this could be due to enzyme aggreg-
ation. Addition of 0.1 ml l μπιοΐ/ΐ captopril to each
incubation mixture completely inhibits the
angiotensin-converting enzyme activity found in the
majority of tissues. Residual activity was detected
only in the stomach and the ileum tissue (fractions
of 0.10 and 0.22 respectively).
The mr of fractions from the same tissue are always
identical.-For example (fig. 1), the major converting
enzyme activity for benign prostatic hyperplasia (n =
5) was always detected at mr = 0.75. The same mr
was also found for normal prostate (n = 2) and
prostatic adenocarcinoma (n = 2).
The reprpducibility of agar gel electrophoresis made
it possible to locate the enzyme activity bands without
staining the gel. Slices containing the enzyme activity
were cut out of the gel and resubmitted to elec-
trophoresis in another agar gel plate. After the second
electrophoresis, the gel was cut again into slices and
assayed s described above.
The same electrophoretic pattern s the original was
always obtained from an excised fraction, which pro-
ves that each fraction found is a single component.
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Fig. l (atoj). Electrophoretic behaviour of angiotensin-converting enzyme in different human body tissues and fluids. Details
are described in the Methods Section. Ordinate: absorbance (A). Abscissa: mobility (mr) relative to albumin
(mr = 1) and Macrodex (mr = 0).
The long incubation time could be the origin of some
artefactual results. In order to exclude the effects of
other proteinases on the Substrate, we added several
proteinase inhibitors to the incubation mixture (12).
The following proteinase inhibitors were used:
Soybean trypsin inhibitor (100 mg/1), N-ethyl-
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Fig. 2. Schematic representation of polyacrylamide elec-
trophoretic patterns of angiotensin-converting enzyme.
Enzyniatic activity fo nd is represented by the blocks.
Details are described in the Methods Section.
maleimide (2 mmol/1), pepstatin (l mg/1) and aprotinin
(2000000 Kunitz inhibitor units per litre). There was
no influence^on the enzyme pattern. Aprotinin also
inhibited the activity of converting enzyme of stom-
ach by 39%, testis enzyme by 10% and sigmoid
enzyme by 5%, without changing the mr of the en-
zyme.
In agar gel, electrophoretic mobility is in the first
instance related to the electrical Charge of the mol-
ecule. Thus the differences found in mr for converting
enzyme in the tissues and fluids studied may be a
function of the number of sialic acid groups in the
angiotensin converting enzyme molecule.
Discussion
The method used for detecting the converting enzyme
activity in the electropherogram has several
advantages: the red quinoneimine dye, which is
formed, gives a qualitative and quantitative esti-
mation of the enzymatic activity present in the agar
gel or polyacrylamide slices. The detection method
has been developed for the quantitative estimation of
angiontensin-converting enzyme in human serum (2)
and results obtained correlate well with the Cush-
man & Cheung (13) technique.
The applicability of the method for experimental
purposes has been demonstrated.
The study of angiotensin converting enzyme in crude
tissue homogenates is complicated by the presence
of other proteolytic enzymes. But available evidence
suggests that the two criteria used for. detecting and
classifying converting enzyme truly distinguish this
enzyme from other known aminopeptidases,
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peptidylpeptidases and proteases. The cleavage of the
histidyl-leucine dipeptide from an artificial Substrate
(p-hydroxybenzoyl-glycyl-L-histidyl-L-leucine) has
been accepted for the determination of converting
enzyme activity since the pioneer studies of Cush-
man & Cheung (13). As far äs we know, the second
criterion used, namely the Inhibition of the enzymatic
activity by captopril in low concentration, has only
been described for angiotensin-converting enzyme
(14).
In order to study the multiple forms <rf angiotensin-
converting enzyme activity, other proteases were in-
hibited with various inhibitors, and the Inhibition of
converting enzyme activity by captopril was
exploited. Using similar conditions, we developed twp
reliable techniques for determining the elec-
trophoretic behaviour of angiotensin-converting en-
zyme. In several human tissues and fluids, the enzyme
can be resolved into two or more fractions with
distinct electrophoretic mobilities.
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